カテゴリ： Allied Market Research, 世界, 医療/バイオ

月経痛治療のグローバル市場（2021〜2031）：一次性月経困難症、二次性月経困難症

■ 英語タイトル：Menstrual Cramps Treatment Market By Type (Primary Dysmenorrhea, Secondary Dysmenorrhea), By Treatment (Non-steroidal Anti-inflammatory Drugs, Hormonal Therapy), By Distribution Channel (Hospital Pharmacies, Drug stores and Retail Pharmacies, Online Providers): Global Opportunity Analysis and Industry Forecast, 2021-2031

調査会社Allied Market Research社が発行したリサーチレポート（データ管理コード：ALD23FB146）■ 発行会社/調査会社：Allied Market Research
■ 商品コード：ALD23FB146
■ 発行日：2022年10月
■ 調査対象地域：グローバル
■ 産業分野：医療
■ ページ数：207
■ レポート言語：英語
■ レポート形式：PDF
■ 納品方式：Eメール（受注後24時間以内）
■ 販売価格オプション（消費税別）
Online Only（1名閲覧、印刷不可）USD3,570 ⇒換算￥542,640見積依頼/購入/質問フォーム
Single User（1名閲覧）USD5,730 ⇒換算￥870,960見積依頼/購入/質問フォーム
Enterprise User（閲覧人数無制限）USD9,600 ⇒換算￥1,459,200見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご購入に関する詳細案内はご利用ガイドでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※Eメールによる納品の場合、通常ご注文当日～2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行・送付致します。（請求書発行日より2ヶ月以内の銀行振込条件、カード払いも可能）
※Allied Market Research社の概要及び新刊レポートはこちらでご確認いただけます。
★グローバルリサーチ資料[月経痛治療のグローバル市場（2021〜2031）：一次性月経困難症、二次性月経困難症]についてメールでお問い合わせはこちら
*** レポート概要（サマリー）***

Allied Market Research社の本市場調査レポートは、世界の月経痛治療市場を総合的に調査・分析した資料であり、イントロダクション、エグゼクティブサマリー、市場概要、種類別（一次性月経困難症、二次性月経困難症）分析、治療別（非ステロイド性抗炎症薬、ホルモン治療）分析、流通チャネル別（病院薬局、ドラッグストア・小売薬局、オンライン供給者）分析、地域別（北米、ヨーロッパ、アジア太平洋、中南米・中東・アフリカ）分析、企業状況、企業情報などを掲載しています。また、本レポートは、AbbVie Inc.、Bayer AG、Johnson and Johnson、Taj Pharmaceuticals Limited、Torrent Pharmaceuticals Ltd.、Abbott Laboratories、Dr. Reddy's Laboratories Ltd.、Pfizer Inc.、GlaxoSmithKline plc、Sun Pharmaceutical Industries Ltd.などの企業情報を含んでいます。
・イントロダクション
・エグゼクティブサマリー
・市場概要
・世界の月経痛治療市場規模：種類別
- 一次性月経困難症における市場規模
- 二次性月経困難症における市場規模
・世界の月経痛治療市場規模：治療別
- 非ステロイド性抗炎症薬における市場規模
- ホルモン治療における市場規模
・世界の月経痛治療市場規模：流通チャネル別
- 病院薬局チャネルの市場規模
- ドラッグストア・小売薬局チャネルの市場規模
- オンライン供給者チャネルの市場規模
・世界の月経痛治療市場規模：地域別
- 北米の月経痛治療市場規模
- ヨーロッパの月経痛治療市場規模
- アジア太平洋の月経痛治療市場規模
- 中南米・中東・アフリカの月経痛治療市場規模
・企業状況
・企業情報

月経痛とは、下腹部の強いけいれん性の痛みのことです。多くの女性が生理の直前や生理中に生理痛を経験します。子宮内膜症や子宮筋腫などの病気が原因で起こることもあります。月経痛の症状には、下腹部のズキズキした痛みやけいれん性の痛み、腰や太ももの痛みなどがあります。また、吐き気、緩い便、頭痛、めまいを経験する女性もいます。

世界の月経痛治療市場の成長は、女性の月経痛患者の増加による月経痛治療に対する需要の増加が主な要因です。また、月経痛治療に対する意識の高まりが、月経痛治療市場の成長をさらに後押ししています。しかし、月経痛治療に関する知識の不足や、吐き気、便秘、嘔吐といった月経痛治療の副作用が市場成長の妨げとなっています。逆に、新興市場における成長機会と世界的な支出の急増は、市場プレーヤーに有利な機会を提供すると予想されます。

生理痛治療市場は、種類、治療法、流通チャネル、地域に区分されます。種類別では、市場は原発性月経困難症と続発性月経困難症に分類されます。治療薬別では、市場は非ステロイド性抗炎症薬とホルモン療法に分別されます。流通チャネル別では、市場は病院薬局、ドラッグストア・小売薬局、オンラインプロバイダーに分類されます。地域別では、北米（米国、カナダ、メキシコ）、欧州（ドイツ、フランス、英国、イタリア、スペイン、その他欧州）、アジア太平洋（日本、中国、オーストラリア、インド、韓国、その他アジア太平洋）、LAMEA（ブラジル、南アフリカ、サウジアラビア、その他LAMEA）に市場を分けて分析しています。

世界の月経痛治療市場で事業を展開する主な主要企業は、Abbott Laboratories, AbbVie Inc., Bayer AG, Dr. Reddy’s Laboratories Ltd., GlaxoSmithKline plc, Johnson & Johnson Private Limited, Pfizer Inc., Sun Pharmaceutical Industries Ltd., Taj Pharmaceuticals Limited, Torrent Pharmaceuticalsです。

〈ステークホルダーにとっての主なメリット〉
・本レポートは、2021年から2031年までの月経痛治療市場分析の市場セグメント、現在の動向、予測、ダイナミクスを定量的に分析し、月経痛治療市場の有力な市場機会を特定します。
・市場調査は、主要な促進要因、阻害要因、機会に関する情報とともに提供されます。
・ポーターのファイブフォース分析により、バイヤーとサプライヤーの潜在力を明らかにし、ステークホルダーが利益重視のビジネス決定を下し、サプライヤーとバイヤーのネットワークを強化できるようにします。
・月経痛治療市場の細分化に関する詳細な分析により、市場機会を見極めます。
・各地域の主要国を世界市場への収益貢献度に応じてマッピングしています。
・市場プレイヤーのポジショニングはベンチマーキングを容易にし、市場プレイヤーの現在のポジションを明確に理解することができます。
・月経痛治療の地域別および世界市場動向、主要企業、市場セグメント、応用分野、市場成長戦略の分析を含みます。

〈主要市場セグメント〉
種類別
原発性月経困難症
二次性月経困難症

治療法別
非ステロイド性抗炎症薬
ホルモン療法

流通チャネル別
病院薬局
ドラッグストア＆小売薬局
オンラインプロバイダー

地域別
・北米
米国
カナダ
メキシコ
・ヨーロッパ
ドイツ
フランス
イギリス
イタリア
スペイン
その他のヨーロッパ
・アジア太平洋
日本
中国
インド
オーストラリア
韓国
その他のアジア太平洋地域
・LAMEA
ブラジル
サウジアラビア
南アフリカ
その他のLAMEA地域

〈主要市場プレイヤー〉
AbbVie Inc.
Bayer AG
Johnson and Johnson
Taj Pharmaceuticals Limited
Torrent Pharmaceuticals Ltd.
Abbott Laboratories
Dr. Reddy’s Laboratories Ltd.
Pfizer Inc.
GlaxoSmithKline plc
Sun Pharmaceutical Industries Ltd.

世界の市場調査レポート販売サイト（H&Iグローバルリサーチ株式会社運営）
*** レポート目次（コンテンツ）***

CHAPTER 1:INTRODUCTION
1.1.Report description
1.2.Key market segments
1.3.Key benefits to the stakeholders
1.4.Research Methodology
1.4.1.Secondary research
1.4.2.Primary research
1.4.3.Analyst tools and models
CHAPTER 2:EXECUTIVE SUMMARY
2.1.Key findings of the study
2.2.CXO Perspective
CHAPTER 3:MARKET OVERVIEW
3.1.Market definition and scope
3.2.Key findings
3.2.1.Top investment pockets
3.3.Porter’s five forces analysis
3.4.Top player positioning
3.5.Market dynamics
3.5.1.Drivers
3.5.2.Restraints
3.5.3.Opportunities
3.6.COVID-19 Impact Analysis on the market
CHAPTER 4: MENSTRUAL CRAMPS TREATMENT MARKET, BY TYPE
4.1 Overview
4.1.1 Market size and forecast
4.2 Primary Dysmenorrhea
4.2.1 Key market trends, growth factors and opportunities
4.2.2 Market size and forecast, by region
4.2.3 Market share analysis by country
4.3 Secondary Dysmenorrhea
4.3.1 Key market trends, growth factors and opportunities
4.3.2 Market size and forecast, by region
4.3.3 Market share analysis by country
CHAPTER 5: MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT
5.1 Overview
5.1.1 Market size and forecast
5.2 Non-steroidal Anti-inflammatory Drugs
5.2.1 Key market trends, growth factors and opportunities
5.2.2 Market size and forecast, by region
5.2.3 Market share analysis by country
5.3 Hormonal Therapy
5.3.1 Key market trends, growth factors and opportunities
5.3.2 Market size and forecast, by region
5.3.3 Market share analysis by country
CHAPTER 6: MENSTRUAL CRAMPS TREATMENT MARKET, BY DISTRIBUTION CHANNEL
6.1 Overview
6.1.1 Market size and forecast
6.2 Hospital Pharmacies
6.2.1 Key market trends, growth factors and opportunities
6.2.2 Market size and forecast, by region
6.2.3 Market share analysis by country
6.3 Drug stores and Retail Pharmacies
6.3.1 Key market trends, growth factors and opportunities
6.3.2 Market size and forecast, by region
6.3.3 Market share analysis by country
6.4 Online Providers
6.4.1 Key market trends, growth factors and opportunities
6.4.2 Market size and forecast, by region
6.4.3 Market share analysis by country
CHAPTER 7: MENSTRUAL CRAMPS TREATMENT MARKET, BY REGION
7.1 Overview
7.1.1 Market size and forecast
7.2 North America
7.2.1 Key trends and opportunities
7.2.2 North America Market size and forecast, by Type
7.2.3 North America Market size and forecast, by Treatment
7.2.4 North America Market size and forecast, by Distribution Channel
7.2.5 North America Market size and forecast, by country
7.2.5.1 U.S.
7.2.5.1.1 Key market trends, growth factors and opportunities
7.2.5.1.2 Market size and forecast, by Type
7.2.5.1.3 Market size and forecast, by Treatment
7.2.5.1.4 Market size and forecast, by Distribution Channel
7.2.5.2 Canada
7.2.5.2.1 Key market trends, growth factors and opportunities
7.2.5.2.2 Market size and forecast, by Type
7.2.5.2.3 Market size and forecast, by Treatment
7.2.5.2.4 Market size and forecast, by Distribution Channel
7.2.5.3 Mexico
7.2.5.3.1 Key market trends, growth factors and opportunities
7.2.5.3.2 Market size and forecast, by Type
7.2.5.3.3 Market size and forecast, by Treatment
7.2.5.3.4 Market size and forecast, by Distribution Channel
7.3 Europe
7.3.1 Key trends and opportunities
7.3.2 Europe Market size and forecast, by Type
7.3.3 Europe Market size and forecast, by Treatment
7.3.4 Europe Market size and forecast, by Distribution Channel
7.3.5 Europe Market size and forecast, by country
7.3.5.1 Germany
7.3.5.1.1 Key market trends, growth factors and opportunities
7.3.5.1.2 Market size and forecast, by Type
7.3.5.1.3 Market size and forecast, by Treatment
7.3.5.1.4 Market size and forecast, by Distribution Channel
7.3.5.2 France
7.3.5.2.1 Key market trends, growth factors and opportunities
7.3.5.2.2 Market size and forecast, by Type
7.3.5.2.3 Market size and forecast, by Treatment
7.3.5.2.4 Market size and forecast, by Distribution Channel
7.3.5.3 UK
7.3.5.3.1 Key market trends, growth factors and opportunities
7.3.5.3.2 Market size and forecast, by Type
7.3.5.3.3 Market size and forecast, by Treatment
7.3.5.3.4 Market size and forecast, by Distribution Channel
7.3.5.4 Italy
7.3.5.4.1 Key market trends, growth factors and opportunities
7.3.5.4.2 Market size and forecast, by Type
7.3.5.4.3 Market size and forecast, by Treatment
7.3.5.4.4 Market size and forecast, by Distribution Channel
7.3.5.5 Spain
7.3.5.5.1 Key market trends, growth factors and opportunities
7.3.5.5.2 Market size and forecast, by Type
7.3.5.5.3 Market size and forecast, by Treatment
7.3.5.5.4 Market size and forecast, by Distribution Channel
7.3.5.6 Rest of Europe
7.3.5.6.1 Key market trends, growth factors and opportunities
7.3.5.6.2 Market size and forecast, by Type
7.3.5.6.3 Market size and forecast, by Treatment
7.3.5.6.4 Market size and forecast, by Distribution Channel
7.4 Asia-Pacific
7.4.1 Key trends and opportunities
7.4.2 Asia-Pacific Market size and forecast, by Type
7.4.3 Asia-Pacific Market size and forecast, by Treatment
7.4.4 Asia-Pacific Market size and forecast, by Distribution Channel
7.4.5 Asia-Pacific Market size and forecast, by country
7.4.5.1 Japan
7.4.5.1.1 Key market trends, growth factors and opportunities
7.4.5.1.2 Market size and forecast, by Type
7.4.5.1.3 Market size and forecast, by Treatment
7.4.5.1.4 Market size and forecast, by Distribution Channel
7.4.5.2 China
7.4.5.2.1 Key market trends, growth factors and opportunities
7.4.5.2.2 Market size and forecast, by Type
7.4.5.2.3 Market size and forecast, by Treatment
7.4.5.2.4 Market size and forecast, by Distribution Channel
7.4.5.3 India
7.4.5.3.1 Key market trends, growth factors and opportunities
7.4.5.3.2 Market size and forecast, by Type
7.4.5.3.3 Market size and forecast, by Treatment
7.4.5.3.4 Market size and forecast, by Distribution Channel
7.4.5.4 Australia
7.4.5.4.1 Key market trends, growth factors and opportunities
7.4.5.4.2 Market size and forecast, by Type
7.4.5.4.3 Market size and forecast, by Treatment
7.4.5.4.4 Market size and forecast, by Distribution Channel
7.4.5.5 South Korea
7.4.5.5.1 Key market trends, growth factors and opportunities
7.4.5.5.2 Market size and forecast, by Type
7.4.5.5.3 Market size and forecast, by Treatment
7.4.5.5.4 Market size and forecast, by Distribution Channel
7.4.5.6 Rest of Asia-Pacific
7.4.5.6.1 Key market trends, growth factors and opportunities
7.4.5.6.2 Market size and forecast, by Type
7.4.5.6.3 Market size and forecast, by Treatment
7.4.5.6.4 Market size and forecast, by Distribution Channel
7.5 LAMEA
7.5.1 Key trends and opportunities
7.5.2 LAMEA Market size and forecast, by Type
7.5.3 LAMEA Market size and forecast, by Treatment
7.5.4 LAMEA Market size and forecast, by Distribution Channel
7.5.5 LAMEA Market size and forecast, by country
7.5.5.1 Brazil
7.5.5.1.1 Key market trends, growth factors and opportunities
7.5.5.1.2 Market size and forecast, by Type
7.5.5.1.3 Market size and forecast, by Treatment
7.5.5.1.4 Market size and forecast, by Distribution Channel
7.5.5.2 Saudi Arabia
7.5.5.2.1 Key market trends, growth factors and opportunities
7.5.5.2.2 Market size and forecast, by Type
7.5.5.2.3 Market size and forecast, by Treatment
7.5.5.2.4 Market size and forecast, by Distribution Channel
7.5.5.3 South Africa
7.5.5.3.1 Key market trends, growth factors and opportunities
7.5.5.3.2 Market size and forecast, by Type
7.5.5.3.3 Market size and forecast, by Treatment
7.5.5.3.4 Market size and forecast, by Distribution Channel
7.5.5.4 Rest of LAMEA
7.5.5.4.1 Key market trends, growth factors and opportunities
7.5.5.4.2 Market size and forecast, by Type
7.5.5.4.3 Market size and forecast, by Treatment
7.5.5.4.4 Market size and forecast, by Distribution Channel
CHAPTER 8: COMPANY LANDSCAPE
8.1. Introduction
8.2. Top winning strategies
8.3. Product Mapping of Top 10 Player
8.4. Competitive Dashboard
8.5. Competitive Heatmap
8.6. Key developments
CHAPTER 9: COMPANY PROFILES
9.1 AbbVie Inc.
9.1.1 Company overview
9.1.2 Company snapshot
9.1.3 Operating business segments
9.1.4 Product portfolio
9.1.5 Business performance
9.1.6 Key strategic moves and developments
9.2 Bayer AG
9.2.1 Company overview
9.2.2 Company snapshot
9.2.3 Operating business segments
9.2.4 Product portfolio
9.2.5 Business performance
9.2.6 Key strategic moves and developments
9.3 Johnson and Johnson
9.3.1 Company overview
9.3.2 Company snapshot
9.3.3 Operating business segments
9.3.4 Product portfolio
9.3.5 Business performance
9.3.6 Key strategic moves and developments
9.4 Taj Pharmaceuticals Limited
9.4.1 Company overview
9.4.2 Company snapshot
9.4.3 Operating business segments
9.4.4 Product portfolio
9.4.5 Business performance
9.4.6 Key strategic moves and developments
9.5 Torrent Pharmaceuticals Ltd.
9.5.1 Company overview
9.5.2 Company snapshot
9.5.3 Operating business segments
9.5.4 Product portfolio
9.5.5 Business performance
9.5.6 Key strategic moves and developments
9.6 Abbott Laboratories
9.6.1 Company overview
9.6.2 Company snapshot
9.6.3 Operating business segments
9.6.4 Product portfolio
9.6.5 Business performance
9.6.6 Key strategic moves and developments
9.7 Dr. Reddy’s Laboratories Ltd.
9.7.1 Company overview
9.7.2 Company snapshot
9.7.3 Operating business segments
9.7.4 Product portfolio
9.7.5 Business performance
9.7.6 Key strategic moves and developments
9.8 GlaxoSmithKline plc
9.8.1 Company overview
9.8.2 Company snapshot
9.8.3 Operating business segments
9.8.4 Product portfolio
9.8.5 Business performance
9.8.6 Key strategic moves and developments
9.9 Pfizer Inc.
9.9.1 Company overview
9.9.2 Company snapshot
9.9.3 Operating business segments
9.9.4 Product portfolio
9.9.5 Business performance
9.9.6 Key strategic moves and developments
9.10 Sun Pharmaceutical Industries Ltd.
9.10.1 Company overview
9.10.2 Company snapshot
9.10.3 Operating business segments
9.10.4 Product portfolio
9.10.5 Business performance
9.10.6 Key strategic moves and developments

LIST OF TABLES
TABLE 1. GLOBAL MENSTRUAL CRAMPS TREATMENT MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 2. MENSTRUAL CRAMPS TREATMENT MARKET FOR PRIMARY DYSMENORRHEA, BY REGION, 2021-2031 (REVENUE, $MILLION)
TABLE 3. MENSTRUAL CRAMPS TREATMENT MARKET FOR PRIMARY DYSMENORRHEA, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
TABLE 4. MENSTRUAL CRAMPS TREATMENT MARKET FOR SECONDARY DYSMENORRHEA, BY REGION, 2021-2031 (REVENUE, $MILLION)
TABLE 5. MENSTRUAL CRAMPS TREATMENT MARKET FOR SECONDARY DYSMENORRHEA, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
TABLE 6. GLOBAL MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT, 2021-2031 (REVENUE, $MILLION)
TABLE 7. MENSTRUAL CRAMPS TREATMENT MARKET FOR NON-STEROIDAL ANTI-INFLAMMATORY DRUGS, BY REGION, 2021-2031 (REVENUE, $MILLION)
TABLE 8. MENSTRUAL CRAMPS TREATMENT MARKET FOR NON-STEROIDAL ANTI-INFLAMMATORY DRUGS, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
TABLE 9. MENSTRUAL CRAMPS TREATMENT MARKET FOR HORMONAL THERAPY, BY REGION, 2021-2031 (REVENUE, $MILLION)
TABLE 10. MENSTRUAL CRAMPS TREATMENT MARKET FOR HORMONAL THERAPY, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
TABLE 11. GLOBAL MENSTRUAL CRAMPS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
TABLE 12. MENSTRUAL CRAMPS TREATMENT MARKET FOR HOSPITAL PHARMACIES, BY REGION, 2021-2031 (REVENUE, $MILLION)
TABLE 13. MENSTRUAL CRAMPS TREATMENT MARKET FOR HOSPITAL PHARMACIES, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
TABLE 14. MENSTRUAL CRAMPS TREATMENT MARKET FOR DRUG STORES AND RETAIL PHARMACIES, BY REGION, 2021-2031 (REVENUE, $MILLION)
TABLE 15. MENSTRUAL CRAMPS TREATMENT MARKET FOR DRUG STORES AND RETAIL PHARMACIES, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
TABLE 16. MENSTRUAL CRAMPS TREATMENT MARKET FOR ONLINE PROVIDERS, BY REGION, 2021-2031 (REVENUE, $MILLION)
TABLE 17. MENSTRUAL CRAMPS TREATMENT MARKET FOR ONLINE PROVIDERS, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
TABLE 18. MENSTRUAL CRAMPS TREATMENT MARKET, BY REGION, 2021-2031 (REVENUE, $MILLION)
TABLE 19. NORTH AMERICA MENSTRUAL CRAMPS TREATMENT MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 20. NORTH AMERICA MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT, 2021-2031 (REVENUE, $MILLION)
TABLE 21. NORTH AMERICA MENSTRUAL CRAMPS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
TABLE 22. NORTH AMERICA MENSTRUAL CRAMPS TREATMENT MARKET, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
TABLE 23. U.S. MENSTRUAL CRAMPS TREATMENT MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 24. U.S. MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT, 2021-2031 (REVENUE, $MILLION)
TABLE 25. U.S. MENSTRUAL CRAMPS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
TABLE 26. CANADA MENSTRUAL CRAMPS TREATMENT MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 27. CANADA MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT, 2021-2031 (REVENUE, $MILLION)
TABLE 28. CANADA MENSTRUAL CRAMPS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
TABLE 29. MEXICO MENSTRUAL CRAMPS TREATMENT MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 30. MEXICO MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT, 2021-2031 (REVENUE, $MILLION)
TABLE 31. MEXICO MENSTRUAL CRAMPS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
TABLE 32. EUROPE MENSTRUAL CRAMPS TREATMENT MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 33. EUROPE MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT, 2021-2031 (REVENUE, $MILLION)
TABLE 34. EUROPE MENSTRUAL CRAMPS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
TABLE 35. EUROPE MENSTRUAL CRAMPS TREATMENT MARKET, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
TABLE 36. GERMANY MENSTRUAL CRAMPS TREATMENT MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 37. GERMANY MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT, 2021-2031 (REVENUE, $MILLION)
TABLE 38. GERMANY MENSTRUAL CRAMPS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
TABLE 39. FRANCE MENSTRUAL CRAMPS TREATMENT MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 40. FRANCE MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT, 2021-2031 (REVENUE, $MILLION)
TABLE 41. FRANCE MENSTRUAL CRAMPS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
TABLE 42. UK MENSTRUAL CRAMPS TREATMENT MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 43. UK MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT, 2021-2031 (REVENUE, $MILLION)
TABLE 44. UK MENSTRUAL CRAMPS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
TABLE 45. ITALY MENSTRUAL CRAMPS TREATMENT MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 46. ITALY MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT, 2021-2031 (REVENUE, $MILLION)
TABLE 47. ITALY MENSTRUAL CRAMPS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
TABLE 48. SPAIN MENSTRUAL CRAMPS TREATMENT MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 49. SPAIN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT, 2021-2031 (REVENUE, $MILLION)
TABLE 50. SPAIN MENSTRUAL CRAMPS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
TABLE 51. REST OF EUROPE MENSTRUAL CRAMPS TREATMENT MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 52. REST OF EUROPE MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT, 2021-2031 (REVENUE, $MILLION)
TABLE 53. REST OF EUROPE MENSTRUAL CRAMPS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
TABLE 54. ASIA-PACIFIC MENSTRUAL CRAMPS TREATMENT MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 55. ASIA-PACIFIC MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT, 2021-2031 (REVENUE, $MILLION)
TABLE 56. ASIA-PACIFIC MENSTRUAL CRAMPS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
TABLE 57. ASIA-PACIFIC MENSTRUAL CRAMPS TREATMENT MARKET, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
TABLE 58. JAPAN MENSTRUAL CRAMPS TREATMENT MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 59. JAPAN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT, 2021-2031 (REVENUE, $MILLION)
TABLE 60. JAPAN MENSTRUAL CRAMPS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
TABLE 61. CHINA MENSTRUAL CRAMPS TREATMENT MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 62. CHINA MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT, 2021-2031 (REVENUE, $MILLION)
TABLE 63. CHINA MENSTRUAL CRAMPS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
TABLE 64. INDIA MENSTRUAL CRAMPS TREATMENT MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 65. INDIA MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT, 2021-2031 (REVENUE, $MILLION)
TABLE 66. INDIA MENSTRUAL CRAMPS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
TABLE 67. AUSTRALIA MENSTRUAL CRAMPS TREATMENT MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 68. AUSTRALIA MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT, 2021-2031 (REVENUE, $MILLION)
TABLE 69. AUSTRALIA MENSTRUAL CRAMPS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
TABLE 70. SOUTH KOREA MENSTRUAL CRAMPS TREATMENT MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 71. SOUTH KOREA MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT, 2021-2031 (REVENUE, $MILLION)
TABLE 72. SOUTH KOREA MENSTRUAL CRAMPS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
TABLE 73. REST OF ASIA-PACIFIC MENSTRUAL CRAMPS TREATMENT MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 74. REST OF ASIA-PACIFIC MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT, 2021-2031 (REVENUE, $MILLION)
TABLE 75. REST OF ASIA-PACIFIC MENSTRUAL CRAMPS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
TABLE 76. LAMEA MENSTRUAL CRAMPS TREATMENT MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 77. LAMEA MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT, 2021-2031 (REVENUE, $MILLION)
TABLE 78. LAMEA MENSTRUAL CRAMPS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
TABLE 79. LAMEA MENSTRUAL CRAMPS TREATMENT MARKET, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
TABLE 80. BRAZIL MENSTRUAL CRAMPS TREATMENT MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 81. BRAZIL MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT, 2021-2031 (REVENUE, $MILLION)
TABLE 82. BRAZIL MENSTRUAL CRAMPS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
TABLE 83. SAUDI ARABIA MENSTRUAL CRAMPS TREATMENT MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 84. SAUDI ARABIA MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT, 2021-2031 (REVENUE, $MILLION)
TABLE 85. SAUDI ARABIA MENSTRUAL CRAMPS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
TABLE 86. SOUTH AFRICA MENSTRUAL CRAMPS TREATMENT MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 87. SOUTH AFRICA MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT, 2021-2031 (REVENUE, $MILLION)
TABLE 88. SOUTH AFRICA MENSTRUAL CRAMPS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
TABLE 89. REST OF LAMEA MENSTRUAL CRAMPS TREATMENT MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 90. REST OF LAMEA MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT, 2021-2031 (REVENUE, $MILLION)
TABLE 91. REST OF LAMEA MENSTRUAL CRAMPS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
TABLE 92.ABBVIE INC.: COMPANY SNAPSHOT
TABLE 93.ABBVIE INC.: OPERATING SEGMENTS
TABLE 94.ABBVIE INC.: PRODUCT PORTFOLIO
TABLE 95.ABBVIE INC.: NET SALES
TABLE 96.ABBVIE INC.: KEY STRATERGIES
TABLE 97.BAYER AG: COMPANY SNAPSHOT
TABLE 98.BAYER AG: OPERATING SEGMENTS
TABLE 99.BAYER AG: PRODUCT PORTFOLIO
TABLE 100.BAYER AG: NET SALES
TABLE 101.BAYER AG: KEY STRATERGIES
TABLE 102.JOHNSON AND JOHNSON: COMPANY SNAPSHOT
TABLE 103.JOHNSON AND JOHNSON: OPERATING SEGMENTS
TABLE 104.JOHNSON AND JOHNSON: PRODUCT PORTFOLIO
TABLE 105.JOHNSON AND JOHNSON: NET SALES
TABLE 106.JOHNSON AND JOHNSON: KEY STRATERGIES
TABLE 107.TAJ PHARMACEUTICALS LIMITED: COMPANY SNAPSHOT
TABLE 108.TAJ PHARMACEUTICALS LIMITED: OPERATING SEGMENTS
TABLE 109.TAJ PHARMACEUTICALS LIMITED: PRODUCT PORTFOLIO
TABLE 110.TAJ PHARMACEUTICALS LIMITED: NET SALES
TABLE 111.TAJ PHARMACEUTICALS LIMITED: KEY STRATERGIES
TABLE 112.TORRENT PHARMACEUTICALS LTD.: COMPANY SNAPSHOT
TABLE 113.TORRENT PHARMACEUTICALS LTD.: OPERATING SEGMENTS
TABLE 114.TORRENT PHARMACEUTICALS LTD.: PRODUCT PORTFOLIO
TABLE 115.TORRENT PHARMACEUTICALS LTD.: NET SALES
TABLE 116.TORRENT PHARMACEUTICALS LTD.: KEY STRATERGIES
TABLE 117.ABBOTT LABORATORIES: COMPANY SNAPSHOT
TABLE 118.ABBOTT LABORATORIES: OPERATING SEGMENTS
TABLE 119.ABBOTT LABORATORIES: PRODUCT PORTFOLIO
TABLE 120.ABBOTT LABORATORIES: NET SALES
TABLE 121.ABBOTT LABORATORIES: KEY STRATERGIES
TABLE 122.DR. REDDY'S LABORATORIES LTD.: COMPANY SNAPSHOT
TABLE 123.DR. REDDY'S LABORATORIES LTD.: OPERATING SEGMENTS
TABLE 124.DR. REDDY'S LABORATORIES LTD.: PRODUCT PORTFOLIO
TABLE 125.DR. REDDY'S LABORATORIES LTD.: NET SALES
TABLE 126.DR. REDDY'S LABORATORIES LTD.: KEY STRATERGIES
TABLE 127.GLAXOSMITHKLINE PLC: COMPANY SNAPSHOT
TABLE 128.GLAXOSMITHKLINE PLC: OPERATING SEGMENTS
TABLE 129.GLAXOSMITHKLINE PLC: PRODUCT PORTFOLIO
TABLE 130.GLAXOSMITHKLINE PLC: NET SALES
TABLE 131.GLAXOSMITHKLINE PLC: KEY STRATERGIES
TABLE 132.PFIZER INC.: COMPANY SNAPSHOT
TABLE 133.PFIZER INC.: OPERATING SEGMENTS
TABLE 134.PFIZER INC.: PRODUCT PORTFOLIO
TABLE 135.PFIZER INC.: NET SALES
TABLE 136.PFIZER INC.: KEY STRATERGIES
TABLE 137.SUN PHARMACEUTICAL INDUSTRIES LTD.: COMPANY SNAPSHOT
TABLE 138.SUN PHARMACEUTICAL INDUSTRIES LTD.: OPERATING SEGMENTS
TABLE 139.SUN PHARMACEUTICAL INDUSTRIES LTD.: PRODUCT PORTFOLIO
TABLE 140.SUN PHARMACEUTICAL INDUSTRIES LTD.: NET SALES
TABLE 141.SUN PHARMACEUTICAL INDUSTRIES LTD.: KEY STRATERGIES

*** 免責事項 ***
https://www.globalresearch.co.jp/disclaimer/
※関連調査資料
  • 月経痛治療のグローバル市場（2022年-2029年）：一次性月経困難症、二次性月経困難症
  • クリ・デュ・チャット症候群治療のグローバル市場（2021〜2031）：理学療法、言語療法、作業療法
  • 感覚異常症治療のグローバル市場（2021〜2031）：急性感覚異常症、慢性感覚異常症
  • 色素異常症治療のグローバル市場（2021〜2031）：白斑、肝斑、その他
  • 子宮内膜症のグローバル市場（2021〜2031）：表在性腹膜病変、子宮内膜腫、その他
    • ※注目の調査資料
     ※当サイト上のレポートデータは弊社H&Iグローバルリサーチ運営のMarketReport.jpサイトと連動しています。
    ※当市場調査資料(ALD23FB146 )"月経痛治療のグローバル市場（2021〜2031）：一次性月経困難症、二次性月経困難症" (英文：Menstrual Cramps Treatment Market By Type (Primary Dysmenorrhea, Secondary Dysmenorrhea), By Treatment (Non-steroidal Anti-inflammatory Drugs, Hormonal Therapy), By Distribution Channel (Hospital Pharmacies, Drug stores and Retail Pharmacies, Online Providers): Global Opportunity Analysis and Industry Forecast, 2021-2031)はAllied Market Research社が調査・発行しており、H&Iグローバルリサーチが販売します。

    ◆H&Iグローバルリサーチのお客様（例）◆


    ※当サイトに掲載していない調査資料も弊社を通してご購入可能ですので、お気軽にご連絡ください。ウェブサイトでは紹介しきれない資料も数多くございます。
    ※無料翻訳ツールをご利用いただけます。翻訳可能なPDF納品ファイルが対象です。ご利用を希望されるお客様はご注文の時にその旨をお申し出ください。